Beyond deficiency; bidirectional metabolic dysregulation between adipose tissue inflammation and vitamin D bioavailability in pediatric obesity

Pediatric obesity is characterized by a bidirectional metabolic dysregulation of vitamin D metabolism within adipose tissue, creating a state of functional deficiency that standard serum measurements often underestimate. Expanded adipose mass acts as a volumetric sink, sequestering fat-soluble vitamin D metabolites and contributing to low circulating 25-hydroxyvitamin D levels, inversely correlated with body fat. Crucially, adipose tissue inflammation drives profound local metabolic disruption, where pro-inflammatory cytokines (TNF-α, IL-6) down-regulate the activating enzyme CYP27B1 (1α-hydroxylase) and upregulate the degrading enzyme CYP24A1 (24-hydroxylase) in adipocytes and macrophages. This ‘double hit’ severely diminishes 1,25-dihydroxyvitamin D [1,25(OH)2D] within the adipose microenvironment, impairing vitamin D receptor (VDR) signaling precisely where it is needed to suppress inflammation. Systemic inflammation further compromises vitamin D status by reducing hepatic CYP2R1 activity, limiting the conversion of vitamin D to 25(OH) D. Additionally, obesity-associated alterations in vitamin D-binding protein (DBP) levels and isoforms may reduce the bioavailable (free) fraction of vitamin D metabolites, exacerbating tissue-level deficiency despite potentially borderline total serum 25(OH)D. Consequently, the combination of sequestration, inflammation-induced dysregulation of activating/degrading enzymes, and altered binding protein dynamics creates a significant disconnect, where standard serum 25(OH)D levels fail to reflect the critical local deficiency of bioactive vitamin D within the inflamed adipose tissue of obese children. This tissue-specific functional deficiency, driven by inflammation, underpins the impaired immunomodulation and perpetuates metabolic dysfunction, highlighting the inadequacy of conventional vitamin D assessment in obesity and necessitating consideration of bioavailability and tissue metabolism.